NervGen Pharma Corp.

NasdaqCM:NGEN Stock Report

Market Cap: US$382.4m

NervGen Pharma Management

Management criteria checks 1/4

NervGen Pharma's CEO is Adam Rogers, appointed in Jul 2025, has a tenure of less than a year. directly owns 0.025% of the company’s shares, worth $96.02K. The average tenure of the management team and the board of directors is 0.6 years and 5 years respectively.

Key information

Adam Rogers

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.03%
Management average tenureless than a year
Board average tenure5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Adam Rogers's remuneration changed compared to NervGen Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-CA$26m

Jun 30 2025n/an/a

-CA$27m

Mar 31 2025n/an/a

-CA$26m

Dec 31 2024n/an/a

-CA$24m

Sep 30 2024n/an/a

-CA$24m

Jun 30 2024n/an/a

-CA$23m

Mar 31 2024n/an/a

-CA$20m

Dec 31 2023n/an/a

-CA$22m

Sep 30 2023n/an/a

-CA$20m

Jun 30 2023n/an/a

-CA$19m

Mar 31 2023n/an/a

-CA$20m

Dec 31 2022CA$126kCA$38k

-CA$21m

Compensation vs Market: Insufficient data to establish whether Adam's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Adam's compensation with company performance.

CEO

Adam Rogers

less than a year
Tenure

Dr. Adam H. Rogers, M.D., is the Co-Founder and Director of Hemera Biosciences Inc. He served as Independent Director of NervGen Pharma Corp. since July 2022. He serves as Director at NervGen Pharma Corp....

Leadership Team

NamePositionTenureCompensationOwnership
Adam Rogers
Chairman & Interim CEOless than a yearno data0.025%
$ 96.0k
Harold Punnett
Co-Founder & Independent Directorno datano data1.48%
$ 5.6m
William Adams
CFO & Corporate Secretary5.9yrsCA$483.68k0.20%
$ 748.1k
Randall Kaye
Chief Medical Advisor & Directorless than a yearno data0.14%
$ 528.1k
0.6yrs
Average Tenure

Experienced Management: NGEN's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Adam Rogers
Chairman & Interim CEO3.5yrsno data0.025%
$ 96.0k
Harold Punnett
Co-Founder & Independent Director9yrsno data1.48%
$ 5.6m
Randall Kaye
Chief Medical Advisor & Director5.3yrsno data0.14%
$ 528.1k
Brian Bayley
Independent Director7.7yrsno data0.71%
$ 2.7m
Michael Weiner
Member of Alzheimer's Disease Scientific Advisory Board4.5yrsno datano data
Jeffrey Cummings
Member of Alzheimer's Disease Scientific Advisory Board5yrsno datano data
Martin Farlow
Member of Alzheimer's Disease Scientific Advisory Board4.5yrsno datano data
George Perry
Member of Alzheimer's Disease Scientific Advisory Board5yrsno datano data
Neil Klompas
Independent Director1.5yrsno datano data
Reisa Sperling
Member of Alzheimer's Disease Scientific Advisory Board4.5yrsno datano data
Henrik Zetterberg
Member of Alzheimer's Disease Scientific Advisory Board5yrsno datano data
Bruce Lamb
Member of Alzheimer's Disease Scientific Advisory Board5yrsno datano data
5.0yrs
Average Tenure
72yo
Average Age

Experienced Board: NGEN's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/27 12:30
End of Day Share Price 2026/01/27 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NervGen Pharma Corp. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott McAuleyParadigm Capital, Inc.
Michael FreemanRaymond James Ltd.
Andre UddinResearch Capital Corporation